Background. Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are important causes of acute neurologic illness. Although the role of acyclovir in treating HSV encephalitis is clear, the role of antiviral therapy in HSV meningitis remains controversial.
Herpes simplex virus (HSV) is a common cause of oral and genital mucocutaneous lesions. HSV type 1 (HSV-1) infection typically occurs in childhood, and the seroprevalence rate in young adults is around 53.9%, according to a recent study by Bradley et al [1] . HSV type 2 (HSV-2) is a common sexually transmitted infection with a seroprevalence of 15.9% in adolescents in the United States [1] . HSV-2 can cause both acute and recurrent meningitis and can occur with associated genital mucocutaneous lesions. Both viruses are neurotropic and are important causes of encephalitis and meningitis. Although HSV-1 typically causes encephalitis and HSV-2 meningitis, this distinction is not absolute, and several series have noted a small percentage of crossover examples, with encephalitis caused by HSV-2 and meningitis caused by HSV-1 [2] [3] [4] [5] [6] [7] .
Although there are excellent studies underscoring the importance of intravenous acyclovir therapy in reducing both mortality and morbidity in patients with HSV encephalitis [2, 4, [8] [9] [10] [11] [12] [13] [14] [15] [16] , the role of antiviral treatment for HSV meningitis remains unclear. The Infectious Disease Society of America's guidelines for the management of encephalitis suggest that prompt initiation of intravenous acyclovir (in <4 days from the onset of clinical symptoms) at a dose of 10 mg/kg every 8 hours for HSV encephalitis is correlated with a decrease in mortality, from 28% to 8% [17] . However, there are no current guidelines outlining how best to manage HSV meningitis.
In this retrospective observational study, we determined the impact of antiviral therapy on the clinical outcomes of patients with cerebrospinal fluid (CSF) specimens positive for HSV by polymerase chain reaction (PCR) who had clinical syndromes of meningitis and encephalitis.
METHODS

Patients
Hennepin County Medical Center is a 475-bed inner-city safetynet hospital in Minneapolis, Minnesota. All patients seen between July 2000 and November 2012 with CSF specimens positive for HSV-1/2 by PCR assay were evaluated. Data was abstracted in a standard format via retrospective review of the electronic health record and included the following: demographic data (age, sex); duration of hospital stay; presence of chronic illness or immunocompromised state; clinical syndrome; physical exam; history of previous episodes of meningitis; laboratory abnormalities including CSF studies; neuroimaging studies when performed; antiviral treatment and side effects; and clinical neurologic outcome (complete neurocognitive recovery vs partial neurocognitive recovery vs residual chronic neurocognitive deficits). Chronic neurocognitive deficits involve any 1 or combination of the following: chronic headaches, focal weakness, paresthesia or sensory deficits, persistent confusion, short or long-term memory impairment, gait instability, speech impairment, impaired executive function, or seizures). Patientepisodes were classified as meningitis if a patient had a clinical syndrome of headache, nausea, vomiting, fever, and neck stiffness without significant change in mental status or focal head computed tomography (CT) or magnetic resonance imaging (MRI) findings, and with CSF examination negative for other etiologies of meningitis according to case definitions established by the Centers for Disease Control and Prevention (CDC) [18] . Patient-episodes were classified as encephalitis if a patient had at least 1 of the following: altered mental status, focal neurologic symptoms and signs, abnormal electroencephalogram, and/or focal lesions on neurologic imaging (CT scan or MRI). Patients were considered immunocompromised if they had human immunodeficiency virus (HIV) with a CD4 T-cell count <500 cells/µL; AIDS if the CD4 T-cell count was <200 cells/µL or had a qualifying AIDS-defining diagnosis by broadly accepted CDC criteria; diabetes mellitus (considered well-controlled if the hemoglobin A1C was <7.0%); alcohol dependence; malignancy; severe malnutrition; or exposed to steroids at doses ≥40 mg daily short-term (for > 5 days) or long-term (15 mg daily for >1 month).
In total, 63 patient-episodes of HSV neurologic infections were documented in 53 patients by HSV PCR assay of CSF. The additional 16 patient-episodes included in this analysis were recurrences of HSV CSF infections (among 6 patients). All patient-episodes involved clinical follow-up in an outpatient setting with a primary care provider, infectious disease clinician, and/or neurologist. The duration of follow-up among patients varied greatly, but ranged from months to years in duration over the study period. Information regarding neurologic outcomes was determined by meticulous chart review to ensure that associated neurologic sequelae were temporally associated with the acute HSV meningitis episode, and also that the neurologic sequelae were determined by the clinician seeing the patient in follow-up to be directly related to the acute HSV meningitis episode.
This study was approved by the Institutional Review Board of the Hennepin County Medical Center.
Laboratory Procedures
A 200-µL CSF specimen was used for nucleic acid extraction using a Qiagen EZ-1 automated extraction virus card version 2.0 (Germantown, Maryland). An in-house-developed qualitative HSV-1/2 PCR based on the procedure described by Tang et al [19] and Mitchell et al [20] was used for the detection of both HSV-1 and HSV-2 DNA in human CSF using homogeneous PCR technology. All CSF specimens were submitted for bacterial cultures to rule out the possibility of bacterial meningitis. We did not routinely submit serologic specimens for antibodies to HSV-1 and HSV-2. All patients had serologic testing for the presence of antibodies to HIV; 14 were HIV positive, all of whom had previously been diagnosed and were on active antiretroviral therapy.
Statistical Analysis
Data was analyzed using Fisher exact probability test to determine significance between central nervous system (CNS) outcome and treatment received. Statistical significance was determined to be P < .05.
RESULTS
From July 2000 to November 2012, we identified 63 patientepisodes of HSV CNS infections in 53 patients. Only 32 CSF specimens from 63 patient-episodes were available for retrospective serotyping (50.7%). However, all patient-episodes were confirmed by HSV PCR of the CSF.
Fifteen patient-episodes in the meningitis treatment group involved immunocompromised hosts (9 with HIV and CD4 (Table 1) . Of these 15 episodes, 3 were treated using supportive care only and were associated with chronic neurologic sequelae (2 with chronic headaches, 1 paresthesias of the hands and discoordination), and 3 with oral antivirals alone (median duration, 7 days; interquartile range [IQR], 5-7 days), all with complete neurologic recovery ( Table 1 ). In the remaining 9 episodes in immunocompromised patients, the patients received a combination of intravenous (for 2-3 days; median, 2.5 days; IQR, 2-3 days) and oral antiviral therapy (median, 10 days; IQR, 7-12), and 2 had persistent neurologic sequelae (1 with paresthesias of the hands, the other left arm pain) ( Table 1) . Two immunocompromised patients (4 patient-episodes) with HSV meningitis had recurrences that were included in this study; both patients (all 4 episodes) were associated with neurologic sequelae ( Table 2 ). The association between treatment in the immunocompromised group and CNS sequelae was significant by Fisher exact probability test (P < .05). Persistent sequelae were documented in 3 of 3 patient-episodes of HSV meningitis in the immunocompromised group that was treated with supportive care alone, whereas only 2 of 12 patient-episodes among immunocompromised hosts treated with specific antiviral therapy were associated with sequelae. There was no correlation between treatment and outcome in the immunocompetent group with meningitis (P = 1.0), as no CNS sequelae were observed in this group. Evaluating all patient-episodes of meningitis (n = 42), 7 patient-episodes (16.6%) were treated with supportive care only (no antiviral therapy), 22 (52.3%) with a combination of oral and intravenous antiviral therapy, 2 (4.7%) with only 1-2 days of intravenous acyclovir until the return of negative culture and PCR results, and 11 (26.2%) with oral antiviral therapy alone (Table 1) . For the 22 episodes treated with combination intravenous and oral therapy (52.4%), the median duration of intravenous therapy was 2 days (IQR, 1.5-2 days) and oral therapy 10 days (IQR, 7-10 days) ( Table 1) .
Six patients in our series had recurrent HSV meningitis (accounting for a total of 16 patient-episodes). Of these 6 patients, 4 patients had 2 separate episodes (8 total episodes), 1 patient had 3 recurrences (3 episodes), and 1 patient experienced 5 recurrent episodes (5 episodes). The remaining 26 patients diagnosed with HSV meningitis had only 1 episode each (accounting for 26 patient-episodes). Twenty-one patients were diagnosed with HSV encephalitis, each with 1 episode (totaling 21 patient-episodes). Overall, therefore, 32 patients had 42 total patient-episodes of HSV meningitis, whereas 21 patients had HSV encephalitis for a total of 53 patients and 63 patient-episodes of CNS infection.
Sixty-five percent of subjects in this series (n = 41) were women, with a median age of 35 years (IQR, 28-44.5 years). Patients with HSV-2 meningitis had higher CSF white blood cell (WBC) counts (median, 328 cells/µL; IQR, 184-483 cells/ µL) than patients with encephalitis (median, 50 cells/µL; IQR, 9-209 cells/µL), with a higher lymphocyte predominance (85.0% vs 74.5%). One episode of HSV meningitis was associated with a normal CSF WBC count of 1 cell/µL, whereas in 3 episodes of HSV encephalitis, patients had normal CSF WBC counts (<5 cells/µL). All other HSV CNS infection patient-episodes had abnormal nucleated cell counts in the CSF (>5 cells/µL).
DISCUSSION
In this study, immunocompromised patients with HSV meningitis had significantly fewer neurologic sequelae (P < .05) when treated with a short course of targeted antiviral therapy. Our data suggest that immunocompromised patients with HSV meningitis may benefit from treatment with acyclovir, valacyclovir, and/or famciclovir for 7-10 days, as neurologic outcomes may be improved by doing so. Although studies show that immunocompetent hosts with HSV meningitis typically improve with or without specific antiviral therapy [2, 5-6, 15, 21-22] , neurologic recovery appears to be less favorable, with an increased likelihood of sequelae in immunocompromised patients.
Currently there are no specific evidence-based guidelines for the management of HSV-associated meningitis. To date, only small observational studies and case reports have been published to inform medical decision making. None of these studies clearly defines the best management of patients with HSV meningitis or describe pertinent clinical neurologic outcomes by treatment category, nor do they examine treatment and outcome difference between immunocompetent and immunocompromised hosts. Mommejia-Marin et al described 18 patients with HSV-associated meningitis who were observed for 90 days after diagnosis [23] ; 13 were severely immunocompromised (10 had AIDS, 8 had lymphoma, and 3 were receiving chemotherapy for either leukemia or lymphoma) [23] . Eleven patients received intravenous antiviral therapy, although in 6, treatment was delayed by a median of 2 days [23] . Two patients with delayed treatment died, and 2 experienced persistent neurologic symptoms [23] . Our study supports their conclusion that early antiviral treatment is indicated for HSV meningitis in the immunocompromised patient [23] . Landry et al describe 23 patients with HSV-2 infections of the CSF, 19 presenting [24] . Of those with meningitis (n = 19), 3 received supportive care alone, 4 received 2-3 weeks of intravenous acyclovir therapy, and the remaining 12 patients received a combination of 1-7 days of intravenous acyclovir followed by 7-21 days of oral antiviral therapy [24] . At least 1 patient with AIDS included in the study was not separately identified and analyzed, and no specific outcome data were described [24] .
There are many limitations to our study. This is a retrospective observational study, with the attendant limitations and a relatively small sample size. Additionally, HSV serotyping was only available for 4 of the 15 episodes in immunocompromised patients and for 32 of the 63 total patient-episodes. Antiviral regimens used were also quite diverse among patient-episodes (route, duration, and type of antiviral varied greatly), which may have had some effect on reported neurologic outcomes. However, this study includes all patients seen at our institution over a 12-year period, with prolonged clinical follow-up and monitoring for persistent neurologic sequelae postinfection.
Based on our analysis, we recommend treating immunocompromised patients with HSV meningitis with a 7-to 10-day course of specific antiviral therapy to improve neurologic outcomes. The emphasis of therapy in acutely ill immunocompetent patients with HSV meningitis should be on rehydration and analgesia rather than intravenous acyclovir therapy, with its attendant risks.
Notes
